SCHEMBL25924028

SCHEMBL25924028

CCCCC(=O)N1CCC2(CCN(CC(CC)CCCC)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
CYP2D6 P10635 4/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
OPRM1 P35372 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
CA2 P00918 2/20 0.38
GNAI3 P08754 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25702021 0.91 CYP2D6 (0.42) L3MBTL1CYP2D6CHRM2HTR1AADRA2A
SCHEMBL25123000 0.90 L3MBTL1 (0.45) L3MBTL1CYP2D6MEN1KMT2ATDP1
SCHEMBL25833307 0.89 CYP2D6 (0.40) L3MBTL1CYP2D6CHRM2HTR1AADRA2A
SCHEMBL25707305 0.89 CA2 (0.41) L3MBTL1CYP2D6CHRM2HTR1AADRA2A
SCHEMBL23946030 0.87 L3MBTL1 (0.49) L3MBTL1CYP2D6MEN1KMT2ATDP1
SCHEMBL25707713 0.87 L3MBTL1 (0.49) L3MBTL1CYP2D6MEN1KMT2ATDP1
SCHEMBL25123599 0.87 CYP2D6 (0.42) L3MBTL1CYP2D6CHRM2HTR1AADRA2A
SCHEMBL24673399 0.86 CYP2D6 (0.41) L3MBTL1CYP2D6CHRM2HTR1AADRA2A
SCHEMBL23696161 0.83 CYP2D6 (0.58) L3MBTL1CYP2D6MEN1KMT2ATDP1
SCHEMBL25654337 0.83 CYP2D6 (0.52) L3MBTL1CYP2D6MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885CYP2D6 3599/4885CHRM2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.